Dot Compliance has upgraded its flagship eQMS solution, Dotty AI, to enhance quality management for the pharmaceutical, biotech, and medical device industries.
The new features include generative and predictive AI tools that provide intelligent insights and recommendations, facilitating effective quality management and regulatory compliance.
With improved anomaly detection and risk mitigation capabilities, the platform allows users to create personalized quality guides based on compliance workflows.
This is the third upgrade since Dotty AI's launch in April 2023, with hundreds of organizations currently utilizing the system. It is designed for companies at any stage of digitization.
Doron Sitbon, Founder and CEO of Dot Compliance, emphasized the company's commitment to providing reliable insights and decision guidance to improve operational efficiency.
He noted that future processes will be more agent-driven and complex, requiring a data-driven culture and well-trained teams to navigate effectively.
This upgrade follows Dot Compliance's recent acquisition of $17.5 million in Series B extension funding.